阿托伐他汀对冠心病患者血浆神经肽Y及胰岛素抵抗的影响  

Effects of Atorvastatin on Plasma Neuropeptide Y and Insulin Resistance in Patients with Coronary Heart Disease

作　　者：马志强[1] 朱启明[1] 丁宇慧[1] 

机构地区：[1]解放军第161中心医院心内科,武汉430010

出　　处：《中国医药导刊》2003年第5期343-344,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:观察阿托伐他汀对冠心病患者血浆神经肽Y及胰岛素抵抗的影响。方法:测定39例冠心病患者(冠心病组)调脂治疗(阿托伐他汀,10mg/d,疗程4周)前后及27例健康人(正常对照组)血脂、血浆神经肽Y、空腹血糖、血清胰岛素,计算胰岛素敏感指数。分析神经肽Y与空腹血清胰岛素和胰岛素敏感指数的相关性。结果:①冠心病组血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇、血浆神经肽Y、空腹血糖、血清胰岛素明显高于对照组,胰岛素敏感指数显著降低;②冠心病组神经肽Y与空腹血清胰岛素和胰岛素敏感指数的密切相关性;③冠心病组调脂治疗后血浆神经肽Y水平显著降低,胰岛素敏感指数明显提高,血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇明显下降。结论:阿托伐他汀可显著降低冠心病患者血浆神经肽Y水平,并能改善胰岛素抵抗状态,且调脂疗效肯定。Objective: To observe effects of atorvastatin on plasma neuropeptide Y(NPY) and insulin resistance in patients with coronary heart disease (CHD). Methods: Fasting serum lipids, glucose, insulin and and plasma NPY were determined in 27 healthy subjects and 39 CHD patients before and after 4 weeks of atorvastatin treatment (10mg/d). Insulin sensitive index(ISI)was caculated. Results : (1)Fasting serum TC, TG, LDLC - C, glucose, insulin and plasma NPY in CHD patients were higher and ISI was lower than that in controls.(2)Plasma NPY in patient group was significantly related to serum insulin and ISI. (3) After atorvastatin treatment, serum TC ,TG, LDLC - C, insulin and plasma NPY in CHD patients obviously decreased with ISI significantly increased. Conclusion: Atorvastatin has bebeficial effects on lowing lipids and plasma NPY and may improve insulin resistance.

关 键 词：冠心病 阿托伐他汀 药物治疗 神经肽Y 胰岛素抵抗 

分 类 号：R541.4[医药卫生—心血管疾病] R972[医药卫生—内科学]